Clinic
SHC Medical Center Toppenish
SHC Medical Center Toppenish was paid $15.10M by Medicaid between Jan 2018 and Dec 2024, across 239 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoSHC MEDICAL CENTER TOPPENISH
TOPPENISH, WA 98948
TOPPENISH, WA 98948
33aNPI1851817308assigned 08/16/2017
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$15.10M
24GClaims476,767
24DCodes billed239
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Washington
Rank by total paid#4 of 31
Median peer was paid$338K
This provider vs. median45×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MATHIESEN, MATHEW controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 67,787 | $2.07M | |
| 2019 | 65,935 | $2.05M | |
| 2020 | 62,631 | $1.83M | |
| 2021 | 68,932 | $2.67M | |
| 2022 | 73,697 | $2.18M | |
| 2023 | 75,493 | $2.20M | |
| 2024incomplete | 62,292 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 35,788 | 33,294 | $4.17M |
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 9,152 | 7,586 | $2.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 22,541 | 20,619 | $2.05M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 7,292 | 6,992 | $772K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 3,381 | 3,223 | $605K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 7,839 | 7,189 | $550K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 3,063 | 2,913 | $466K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 4,872 | 3,847 | $410K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 2,473 | 2,326 | $336K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.7% | 1,336 | 1,302 | $260K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,698 | 1,657 | $215K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,155 | 1,094 | $199K |
227 more codes
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.2% | 697 | $182K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 1,141 | $171K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 1,871 | $161K |
| 80053 | Comprehensive metabolic panel | <1% | 23,731 | $122K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,664 | $115K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 896 | $109K |
| 59025 | Fetal non-stress test | <1% | 780 | $108K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,589 | $94K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,187 | $92K |
| 12001 | <1% | 354 | $68K | |
| 76830 | Ultrasound, transvaginal | <1% | 901 | $67K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 526 | $55K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,054 | $50K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,370 | $49K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,444 | $49K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,353 | $34K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,903 | $29K |
| 73630 | <1% | 1,256 | $26K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 112 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,215 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,166 | $25K |
| 64721 | <1% | 40 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,197 | $24K |
| 84484 | <1% | 5,777 | $24K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 463 | $23K |
| G0378 | Hospital observation service, per hour | <1% | 1,477 | $21K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,756 | $20K |
| 73562 | <1% | 1,240 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,353 | $19K |
| 72100 | <1% | 897 | $18K | |
| 83605 | <1% | 2,917 | $17K | |
| 76642 | <1% | 211 | $17K | |
| 80050 | General health panel | <1% | 2,733 | $16K |
| 83880 | <1% | 3,244 | $15K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $14K |
| 73610 | <1% | 1,228 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,093 | $14K |
| 87040 | <1% | 2,109 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,827 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 279 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 706 | $13K |
| 73030 | <1% | 1,012 | $13K | |
| 80306 | <1% | 5,870 | $13K | |
| 80061 | Lipid panel | <1% | 2,968 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,308 | $12K |
| 90714 | <1% | 778 | $12K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 260 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 642 | $12K |
| 76801 | <1% | 215 | $12K | |
| 82247 | <1% | 1,444 | $12K | |
| 73110 | <1% | 514 | $10K | |
| 84439 | <1% | 1,029 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,988 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,535 | $9K |
| 73130 | <1% | 620 | $8K | |
| 85379 | <1% | 1,256 | $8K | |
| 76536 | <1% | 97 | $8K | |
| 84145 | <1% | 801 | $8K | |
| 99460 | <1% | 90 | $7K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 144 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,790 | $6K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 103 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 69 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,806 | $5K |
| 74018 | <1% | 941 | $4K | |
| 97161 | <1% | 96 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,715 | $4K |
| 86140 | <1% | 1,835 | $4K | |
| 82607 | <1% | 294 | $3K | |
| 73140 | <1% | 349 | $3K | |
| 12011 | <1% | 13 | $3K | |
| 81001 | <1% | 14,397 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,353 | $3K |
| 84702 | <1% | 1,554 | $3K | |
| 76870 | <1% | 27 | $3K | |
| 72040 | <1% | 87 | $3K | |
| 85652 | <1% | 996 | $2K | |
| 82248 | <1% | 464 | $2K | |
| 0002A | <1% | 64 | $2K | |
| 86780 | <1% | 174 | $2K | |
| 73502 | <1% | 172 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 56 | $2K |
| 96367 | <1% | 135 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 29 | $2K |
| 83735 | <1% | 4,971 | $2K | |
| 83690 | <1% | 7,595 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $2K |
| 87186 | <1% | 3,231 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 133 | $2K |
| 87070 | <1% | 1,184 | $2K | |
| 81025 | <1% | 5,733 | $2K | |
| 87081 | <1% | 5,171 | $1K | |
| 76641 | <1% | 16 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,563 | $1K |
| 70486 | <1% | 54 | $1K | |
| 73080 | <1% | 68 | $1K | |
| 85610 | <1% | 3,698 | $1K | |
| 0001A | <1% | 66 | $1K | |
| 85027 | <1% | 330 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 33 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 108 | $979.40 |
| 81003 | <1% | 2,738 | $935.50 | |
| J3490 | Unclassified drugs | <1% | 118 | $925.97 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,961 | $915.46 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,034 | $907.92 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 319 | $884.02 |
| 83550 | <1% | 138 | $879.91 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $844.13 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $844.11 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 838 | $829.69 |
| 87807 | <1% | 1,312 | $782.25 | |
| 0012A | <1% | 25 | $741.66 | |
| 87077 | <1% | 1,044 | $727.66 | |
| 87205 | <1% | 1,427 | $698.66 | |
| 82728 | <1% | 134 | $687.27 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,026 | $685.99 |
| 86900 | <1% | 668 | $655.16 | |
| 84703 | <1% | 1,799 | $612.80 | |
| 80076 | <1% | 120 | $609.85 | |
| 86803 | <1% | 228 | $606.11 | |
| 82150 | <1% | 1,841 | $589.93 | |
| 87088 | <1% | 1,317 | $578.71 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 38 | $557.84 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,705 | $549.34 |
| 86038 | <1% | 88 | $548.26 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 14 | $439.44 |
| 72070 | <1% | 14 | $418.10 | |
| 83540 | <1% | 139 | $409.55 | |
| 86704 | <1% | 76 | $319.20 | |
| 73090 | <1% | 14 | $276.78 | |
| 85730 | <1% | 2,195 | $254.13 | |
| 96376 | <1% | 2,429 | $252.86 | |
| 87147 | <1% | 938 | $246.18 | |
| 80074 | <1% | 73 | $228.89 | |
| 86901 | <1% | 626 | $222.38 | |
| 86141 | <1% | 44 | $207.93 | |
| 0011A | <1% | 12 | $200.00 | |
| 87340 | <1% | 44 | $193.17 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,472 | $182.41 |
| 97035 | <1% | 24 | $157.47 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,127 | $144.28 |
| 86708 | <1% | 27 | $136.05 | |
| 86706 | <1% | 27 | $136.05 | |
| 86701 | <1% | 56 | $128.50 | |
| 86850 | <1% | 72 | $121.80 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,307 | $113.99 |
| 86317 | <1% | 13 | $111.50 | |
| 83615 | <1% | 244 | $105.57 | |
| 82570 | <1% | 14 | $85.53 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,822 | $84.05 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,254 | $80.38 |
| 86702 | <1% | 56 | $78.32 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,111 | $74.00 |
| 84153 | <1% | 13 | $72.95 | |
| 85651 | <1% | 87 | $65.81 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,007 | $60.56 |
| 82140 | <1% | 85 | $58.87 | |
| 73590 | <1% | 12 | $51.13 | |
| 86200 | <1% | 12 | $41.88 | |
| 82550 | <1% | 88 | $38.09 | |
| 84550 | <1% | 13 | $32.96 | |
| 82043 | <1% | 12 | $29.66 | |
| 81015 | <1% | 36 | $27.35 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 637 | $23.08 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,945 | $15.09 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,206 | $13.81 |
| 88342 | <1% | 223 | $13.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,365 | $13.18 |
| 87075 | <1% | 13 | $12.84 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,323 | $10.91 |
| 82077 | <1% | 194 | $8.11 | |
| 81002 | <1% | 319 | $7.54 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,842 | $2.50 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,717 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 368 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,801 | $0.00 |
| 99152 | 0% | 689 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 209 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 67 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 384 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,903 | $0.00 |
| 80179 | 0% | 38 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 49 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 155 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 70 | $0.00 |
| 85014 | 0% | 29 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 40 | $0.00 |
| 80143 | 0% | 41 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 34 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 14 | $0.00 |
| 29125 | 0% | 15 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 106 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 47 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 34 | $0.00 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 18 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 466 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,897 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 267 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,252 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,135 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,199 | $0.00 |
| 82803 | 0% | 45 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,842 | $0.00 |
| 71101 | 0% | 13 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 350 | $0.00 |
| 74019 | 0% | 12 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 277 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 280 | $0.00 |
| 94761 | 0% | 307 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 142 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 80 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 198 | $0.00 |
| 94760 | 0% | 539 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 40 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,024 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 270 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 64 | $0.00 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 12 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 12 | $0.00 |
| 80047 | 0% | 14 | $0.00 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | 0% | 13 | $0.00 |
| 80320 | 0% | 62 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHIESEN, MATHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sunnyside Community Hospital Association | Sunnyside, WA | $55.09M |
| SHC Medical Center - Yakima | Yakima, WA | $6.93M |
| SHC Medical Center Toppenish | Union Gap, WA | $4.99M |
| Sunnyside Community Hospital Association | Prosser, WA | $2.35M |
| SHC Medical Center Toppenish | Zillah, WA | $663K |
| SHC Medical Center Toppenish | Toppenish, WA | $381K |
| Sunnyside Community Hospital Association | Union Gap, WA | $316K |
| Sunnyside Community Hospital | Yakima, WA | $51K |
| SHC Medical Center - Yakima | Yakima, WA | $11K |
| Sunnyside Community Hospital | Sunnyside, WA | $4K |
| Sunnyside Community Hospital | Sunnyside, WA | $860.66 |
| Sunnyside Community Hospital Association | Yakima, WA | $839.86 |
| Sunnyside Community Hospital Association | Union Gap, WA | $696.97 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.